Analysis of OS according to tumour subtype showed significant differences among stage IV patients with bone metastases, and the five-year survival rate was 32.7% for HR+/HER2- patients, 48.8% for HR+/HER2+ patients, 8.6% for HR−/HER2- patients and 36.1% for HR−/HER2+ patients. This evidence concerns the gene ERBB2 and neoplasm.